A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

The firm will evaluate its EGFR-targeted ADC ALX2004 in advanced non-small cell lung, head and neck, esophageal, and colorectal cancers.

Precigen had sought accelerated approval for Papzimeos, but the FDA opted to grant it full approval after reviewing data from a Phase I/II trial.

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...